SDG solutions through partnerships
This week heads of state and business leaders from around the world meet in New York. The purpose is clear; everybody wants to find solutions on how to achieve the world’s greatest challenges, the UN Sustainable Development Goals (SDGs).
LEO Pharma is no exception. That is why we are present at the 74th session of the UN General Assembly (UNGA) in New York to show our commitment to the SDGs with special focus on SDG 3 ‘Good health and well-being’.
Mette Vestergaard, Chair of LEO Pharma’s CSR Board and EVP of Global People and Business Transformation shares some highlights from her engagements at UNGA:
“I am excited to experience the shared agreement among stakeholders attending healthcare sessions at UNGA that non-communicable diseases like dermatology need to be raised on the global health agenda. Strategic partnerships across the board are pivotal to enable the systemic change needed to achieve the SDGs and help people with skin diseases live better lives. The fact that state and business leaders meet in New York to put action behind the words is a great step towards realizing SDG 3.”
Innovation through partnerships
A theme of shared responsibility and a need to collaborate was repeated at several of the UNGA sessions Mette Vestergaard participated in.
“Being part of UNGA really underlined the importance of working together across industries and sectors to identify concrete solutions to achieving the SDGs,” explains Mette Vestergaard and draws a parallel to the way LEO Pharma’s innovation eco-system is working.
“Co-creating SDG solutions is very much in line with the way we innovate at LEO Pharma to find new treatments for patients. We acknowledge that more minds work better than one. That is why we have extensive collaborations between our own R&D organization and more than 400 academic and institutional research centers, industry partners and patient organizations worldwide. We make the world our lab and collaborate with experts globally to enhance our knowledge of skin diseases and explore new potential treatments.”
LEO Pharma is committed to deliver on SDG 3. We are therefore using our strong innovation engine to explore solutions that can improve the quality of lives of people with skin diseases.
